Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.8500 (-2.06%) ($12.8500 - $12.8500) on Mon. Sep. 18, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.29% (three month average) | RSI | 52 | Latest Price | $12.8500(-2.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.5% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(69%) IBB(64%) ARKG(59%) IWO(47%) BWX(46%) | Factors Impacting FOLD price | FOLD will decline at least -1.145% in a week (0% probabilities). TBT(-32%) UUP(-18%) VXX(-11%) VIXM(-2%) URA(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.145% (StdDev 2.29%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $13.08(-1.76%) | 10 Day Moving Average | $12.91(-0.46%) | 20 Day Moving Average | $12.85(0%) | To recent high | -6.8% | To recent low | 9.1% | Market Cap | $3.318b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |